Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.
Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients.
MicroRNAs: The Role in Autoimmune Inflammation.
Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Movement and structure of mitochondria in oligodendrocytes and their myelin sheaths.
Autoimmune sleep disorders.
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
The endocannabinoid system and multiple sclerosis.
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
Effect of vitamin D on MS activity by disease-modifying therapy class.
Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.
Women's Issues in Multiple Sclerosis.
CLIC1 regulates dendritic cell antigen processing and presentation by modulating phagosome acidification and proteolysis.
Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.
Clarity Extension Study
Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis: Are There Lessons to Be Learned?
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease.
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies.
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.

Pages